EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Bayes at the Bedside: Biomarkers in Situations of Clinical Uncertainty

Uwe Klaus Zettl, Michael Hecker iD

Diagnostics · 31.05.2026 · 16 (11) · 1699

DOI: 10.3390/diagnostics16111699 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diagnostics, online erschienen am 31.05.2026. Verfasst von Uwe Klaus Zettl und 1 weiteren Autor:innen. Beteiligte Einrichtung: Neuroimmunology Section, Department of Neurology, Rostock University Medical Centre, 18147 Rostock, Germany. Die Arbeit nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Laboratory biomarkers influence a large proportion of clinical decision-making, yet their application is often limited by incomplete validation and context-dependent interpretability. Serum neurofilament light chain (sNfL), a biomarker of neuroaxonal injury in multiple sclerosis (MS), exemplifies this challenge. Although associated with inflammatory activity, lesion burden, and disability progression at the population level, its translation into individual patient management remains problematic. In this Perspective, we synthesise current literature on sNfL in MS and apply Bayesian diagnostic reasoning as a conceptual framework for its interpretation in individualised MS care. The need for such a framework arises from the heterogeneity of MS pathology, in which subclinical inflammation and neurodegeneration may occur as partly dissociated processes that are incompletely captured by clinical and radiological measures. Consequently, substantial uncertainty persists in disease monitoring and therapeutic decision-making. In this setting, sNfL may provide complementary information, but its interpretation is complicated by biological variability, methodological differences, confounding factors (e.g., age, body mass index, and comorbidities), and the absence of universally validated thresholds. We argue that sNfL should be interpreted within a Bayesian framework, in which biomarker results modify rather than determine the probability of disease activity. Its clinical utility is likely greatest when the pre-test probability is intermediate but remains constrained by uncertainty in both test characteristics and clinical context, leading to uncertainty propagation. Overall, sNfL should be interpreted longitudinally and within multimodal clinical decision models. Further prospective studies are needed to better define its role in individualised MS management.

Schlagwörter

Stichwörter der Autor:innen

Bayesian inferencebiomarkersdiagnostic uncertaintydisease activitymultiple sclerosisneurofilament light chain

Autor:innen und Institutionen

  • Neuroimmunology Section, Department of Neurology, Rostock University Medical Centre, 18147 Rostock, Germany.

ORCID-Profile: Michael Hecker

Zitieren

APA

Zettl, U. K., & Hecker, M. (2026). Bayes at the Bedside: Biomarkers in Situations of Clinical Uncertainty. Diagnostics, 16(11), 1699. https://doi.org/10.3390/diagnostics16111699

Vancouver

Zettl UK, Hecker M. Bayes at the Bedside: Biomarkers in Situations of Clinical Uncertainty. Diagnostics. 2026;16(11):1699. doi:10.3390/diagnostics16111699

BibTeX
@article{Zettl2026,
  author = {Zettl, Uwe Klaus and Hecker, Michael},
  title = {Bayes at the Bedside: Biomarkers in Situations of Clinical Uncertainty},
  journal = {Diagnostics},
  year = {2026},
  volume = {16},
  number = {11},
  pages = {1699},
  doi = {10.3390/diagnostics16111699}
}
Kostenlos starten →